Dr. Nassir is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5901 W Olympic Blvd
Ste 505
Los Angeles, CA 90036Phone+1 323-930-2324Fax+1 323-395-5784
Summary
- Dr. Youram Nassir, founder and director of Cancer Care Institute, passionately cares for patients who have been told their case was hopeless. He always goes the extra mile for patients and never gives up. He provides the highest quality of care and the latest treatments in an honest, supportive, respectful, and compassionate manner. He works with multiple specialists in different medical arenas, including surgery, neurosurgery, thoracic surgery, radiation oncology, gastroenterology, and pulmonary critical care in order to devise cutting-edge treatments for various cancers, including brain, lung, liver, pancreas, prostate, ovarian, breast, leukemia, multiple myeloma, and lymphoma.
Education & Training
- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1999 - 2002
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 1999
- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1996 - 1997
- David Geffen School of Medicine at UCLAClass of 1996
Certifications & Licensure
- CA State Medical License 1998 - 2025
Awards, Honors, & Recognition
- Patient's Choice Award
- Compassionate Doctor Recognition
- Yachad Outreach Center Acts of Loving and Kindness Award
Publications & Presentations
PubMed
- 1 citationsDurable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy.Michael Kozak, Wesley Rubenstein, Derick Okwan-Duodu, Kenneth Friedman, Youram Nassir
Transfusion. 2023-06-01 - 9 citationsSafety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myelomaAlexa Cohen, Tanya M. Spektor, Laura Stampleman, Alberto Bessudo, Peter Rosen
British Journal of Haematology. 2018-01-01 - 2 citationsSafety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.Aleksandra Vidisheva, James Wang, Tanya M. Spektor, Jacob D. Bitran, Jose Lutzky
Supportive Care in Cancer. 2017-04-28
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: